Rucaparib: tested on its own
24 studies: no other medicine in its arm. Page 1 of 1. Open to participants first (0), then studies with results posted, then the rest; newest registration first within each.
- CATCH-R: A Rollover Study to Provide Continued Access to RucaparibCompletedNCT04676334Phase 3Results postedReport a problem
- A Study to Evaluate Rucaparib in Participants With Solid Tumors and With Deleterious Mutations in HRR GenesTerminatedNCT04171700Phase 2Results postedReport a problem
- Rucaparib in Treating Patients With Genomic LOH High and/or Deleterious BRCA1/2 Mutation Stage IV or Recurrent Non-small Cell Lung Cancer (A Lung-MAP Treatment Trial)CompletedNCT03845296Phase 2Results postedReport a problem
- Rucaparib vs Placebo Maintenance Therapy in Metastatic and Recurrent Endometrial CancerCompletedNCT03617679Phase 2Results postedReport a problem
- A Study of Rucaparib Administered With Radiation in Patients With Triple Negative Breast Cancer With an Incomplete Response Following ChemotherapyCompletedNCT03542175Phase 1Results postedReport a problem
- Rucaparib in Nonmetastatic prOstAte With BRCAnessTerminatedNCT03533946Phase 2Results postedReport a problem
- Trial of Rucaparib in Patients With Metastatic Hormone-Sensitive Prostate Cancer Harboring Germline DNA Repair Gene MutationsCompletedNCT03413995Phase 2Results postedReport a problem
- Rucaparib in Patients With Locally Advanced or Metastatic Urothelial CarcinomaTerminatedNCT03397394Phase 2Results postedReport a problem
- Maintenance Rucaparib in BRCA1, BRCA2 or PALB2 Mutated Pancreatic Cancer That Has Not Progressed on Platinum-based TherapyTerminatedNCT03140670Phase 2Results postedReport a problem
- A Study of Rucaparib Versus Physician's Choice of Therapy in Participants With Metastatic Castration-resistant Prostate Cancer and Homologous Recombination Gene DeficiencyCompletedNCT02975934Phase 3Results postedReport a problem
- A Study of Rucaparib in Patients With Metastatic Castration-resistant Prostate Cancer and Homologous Recombination Gene DeficiencyCompletedNCT02952534Phase 2Results postedReport a problem
- ARIEL4: A Study of Rucaparib Versus Chemotherapy BRCA Mutant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer PatientsCompletedNCT02855944Phase 3Results postedReport a problem
- Phase 3 Study of Rucaparib as Switch Maintenance After Platinum in Relapsed High Grade Serous or Endometrioid Ovarian Cancer (ARIEL3)CompletedNCT01968213Phase 3Results postedReport a problem
- A Study of Rucaparib in Patients With Platinum-Sensitive, Relapsed, High-Grade Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (ARIEL2)CompletedNCT01891344Phase 2Results postedReport a problem
- A Study of Oral Rucaparib in Patients With a Solid Tumor (Phase I) or With gBRCA Mutation Ovarian Cancer (Phase II)CompletedNCT01482715Phase 1/2Results postedReport a problem
- Rucaparib MAintenance After Bevacizumab Maintenance Following Carboplatin Based First Line Chemotherapy in Ovarian Cancer PatientsCompletedNCT04227522Phase 3Report a problem
- Window of Opportunity Trial, PARP Inhibitor Rucaparib Affect on PD-L1 Expression in Triple Negative Breast TumorsCompletedNCT03911453Early Phase 1Report a problem
- Rucaparib Maintenance Therapy in Advanced Cervical CancerWithdrawnNCT03795272Phase 2Report a problem
- Rucaparib Hepatic Impairment Study in Patients With a Solid TumorCompletedNCT03521037Phase 1Report a problem
- A Study of Rucaparib in Japanese Patients With a Previously-treated Solid TumorCompletedNCT03499444Phase 1Report a problem
- A Study to Assess the Efficacy of Rucaparib in Metastatic Breast Cancer Patients With a BRCAness Genomic SignatureCompletedNCT02505048Phase 2Report a problem
- A Study of Rucaparib in Patients With Pancreatic Cancer and a Known Deleterious BRCA MutationCompletedNCT02042378Phase 2Report a problem
- Rucaparib(CO-338;Formally Called AG-014699 or PF-0136738) in Treating Patients With Locally Advanced or Metastatic Breast Cancer or Advanced Ovarian CancerCompletedNCT00664781Phase 2Report a problem
- A Phase 2 Study Exploring The Safety And Efficacy Of Novel Drug Treatment In Subjects With Diabetic Macular Edema (DME)WithdrawnNCT00457470Phase 2Report a problem